Moderna beats fourth-quarter revenue estimates

Core Insights - Moderna reported fourth-quarter revenue of $678 million, exceeding Wall Street estimates of $626.1 million, driven by better-than-expected sales of its COVID-19 vaccine in the U.S. [1] - The company is facing financial challenges as demand for COVID vaccines has declined significantly since the pandemic peak, prompting efforts to develop new products to sustain revenue and demonstrate the long-term viability of its mRNA technology [1] - Moderna reiterated its expectation of achieving 10% revenue growth by 2026 [1]